Browsing Artículos by Author "Zabolian, Amirhossein"

Now showing items 1-3 of 3

    • Thumbnail

      Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects 

      Mirzaei, Sepideh; Gholami, Mohammad Hossein; Hashemi, Farid; Zabolian, Amirhossein; Vasheghani Farahani, Mahdi; Hushmandi, Kiavash; Zarrabi, Ali; Goldman, Aaron; Ashrafizadeh, Milad; Orive Arroyo, Gorka (Elsevier, 2022-02)
      P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1alpha, miRNAs, and long noncoding ...
    • Thumbnail

      AIE-featured tetraphenylethylene nanoarchitectures in biomedical application: Bioimaging, drug delivery and disease treatment 

      Sarathkumar, Kothanahally S.; Girish, Yarabahally R.; Ashrafizadeh, Milad; Mirzaei, Sepideh; Rakesh, Kadalipura P.; Gholami, Mohammad Hossein; Zabolian, Amirhossein; Hushmandi, Kiavash; Orive Arroyo, Gorka; Kadumudi, Firoz Babu; Dolatshahi-Pirouz, Alireza ORCID; Thakur, Vijay Kumar; Zarrabi, Ali; Makvandi, Pooyan; Rangappa, Kanchugarakoppal S. (Elsevier, 2021-11-15)
      [EN]The development of aggregation-induced emission (AIE) has received extreme considerations from basic and clinical researches. To date, various luminogens with AIE property (AIEgens) have been broadly utilized in ...
    • Thumbnail

      Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression 

      Ashrafizadeh, Milad; Mirzaei, Sepideh; Gholami, Mohammad Hossein; Hashemi, Farid; Zabolian, Amirhossein; Raei, Mehdi; Hushmandi, Kiavash; Zarrabi, Ali; Voelcker, Nicolas H.; Aref, Amir Reza; Hamblin, Michael R.; Varma, Rajender S.; Samarghandian, Saeed; Arostegi, I. J.; Alzola, M.; Kumar, Alan Prem; Thakur, Vijay Kumar; Nabavi, Noushin; Makvandi, Pooyan; Tay, Franklin R.; Orive Arroyo, Gorka (Elsevier, 2021-11-15)
      [EN]An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage ...